Leflunomida Viatris (Leflunomide)

Leflunomide is converted to teriflunomide, which blocks the enzyme dihydroorotate dehydrogenase. This inhibition curtails de novo pyrimidine synthesis, limiting the proliferation of activated lymphocytes, especially T‑cells, thereby reducing the autoimmune inflammation that drives joint damage.

The dosage of Leflunomida Viatris is determined by the prescribing clinician based on the individual’s disease severity, response, and safety profile. Physicians typically start with a loading dose followed by a maintenance dose, but exact amounts should only be set by a qualified healthcare professional.

Leflunomida Viatris is contraindicated in pregnancy because it can cause fetal harm. Women of childbearing potential must use effective contraception while on therapy. The product is also not recommended for breastfeeding mothers, as leflunomide can be excreted in milk and affect the infant.

To request Leflunomida Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Leflunomida Viatris and methotrexate are both DMARDs, but they act via different mechanisms. Leflunomide inhibits pyrimidine synthesis, while methotrexate interferes with folate metabolism. Clinical choice depends on patient tolerance, liver function, and prior response; some patients who do not respond adequately to methotrexate may benefit from leflunomide.

Leflunomida Viatris should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Leflunomida Viatris is taken orally, usually as a tablet swallowed whole with a glass of water. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing and any required loading doses.

The most serious risks include severe liver injury, bone‑marrow suppression leading to neutropenia or anemia, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, blood counts, and any signs of severe skin eruptions.

Leflunomida Viatris should not be used by pregnant women, individuals with severe liver disease, those with active serious infections, or patients with known hypersensitivity to leflunomide or its metabolites. Caution is also advised for patients with significant immunosuppression or uncontrolled hypertension.